On average, it takes 15 years to develop new drugs and can cost more than £2 billion from discovery to launch. Once launched, drugs can be hindered by not matching the right compound to the right patient at the right time. Precision medicine offers an alternative model by developing medicines that are personalised to the patient. It focuses on a deep, molecular knowledge of a particular person’s disease. This approach offers huge benefits not just to patients but healthcare bodies, as well as pharmaceutical and diagnostic industries.
Kinomica has a bioinformatics platform called KScan® that generates insights into the activities of the cell’s proteins and their complex signalling cascades, especially in cancer. KScan uses a database, patented algorithms and a protein activity ranking method to analyse diseased tissue and identify the best match of drug for each patient. This KScan approach offers a ‘hypothesis-free’ way of looking at which cell signalling mechanisms are driving diseases and how best to treat them.
Jane Theaker is the CEO of Kinomica Ltd. Jane is responsible for providing the company’s mission, raising finance to support its commercial aims and overall leadership. She joined the Scale Up Accelerator programme in 2021 and hopes it will provide her with additional leadership skills that will help grow the company from Series A to Series B funding, and eventually to a trade sale or stock market issue.
Kinomica’s KScan platform and world-leading expertise in cell signalling can develop better drugs and diagnostic tests. Jane says: “At Kinomica, we are completely focused on saving patients’ lives, by getting this disruptive technology to the bedside as quickly as we can.”
Associated Programme
